Thromb Haemost 1976; 35(02): 358-363
DOI: 10.1055/s-0038-1647929
Original Article
Schattauer GmbH

The Effect of Halofenate or Halofenate Free Acid on Human, Rat and Guinea Pig Platelet Aggregation

D.H Minsker
1   Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486, USA
,
P.T Jordan
1   Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486, USA
,
P Kling
1   Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486, USA
,
A MacMillan
1   Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486, USA
,
H.B Hucker
1   Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486, USA
,
D.J Tocco
1   Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486, USA
› Author Affiliations
Further Information

Publication History

Received 10 April 1975

Accepted 28 July 1975

Publication Date:
02 July 2018 (online)

Summary

Halofenate free acid (HFA), the major metabolite of the hypolipemic agent halofenate, blocked the secondary phase of human platelet aggregation induced by ADP, epinephrine, or thrombin; higher concentrations of clohbrate free acid (CFA) were required to produce similar inhibitory effects on platelet aggregation. HFA and CFA inhibited collagen-induced aggregation of human, rat, or guinea pig platelets. Halofenate orally administered to rats caused inhibition of collagen-induced aggregation when plasma levels of HFA exceeded 300 μg/ml, a clinically achievable human plasma concentration. The platelet inhibitory effects of clofibrate administration were less than those observed with halofenate administration.

 
  • References

  • 1 Bluhm G. B, Riddle J. M. 1973 Seminars in Arthritis and Rheumatism. 2, 355.
  • 2 Born G. V. R. 1962; Quantitative investigations into the aggregation of blood platelets. Journal of Physiology 162: 67 P.
  • 3 Fanelli G. M, Bohn D. L, Reilly S. S, Baer J. E. 1972; Renal excretion and uricosuric properties of halofenate, a hypolipidemicuricosuric agent, in the chimpanzee. Journal of Pharmacology and Experimental Therapeutics 180: 377.
  • 4 Gilfillan J. L, Hunt V. M, Huff J. W. 1971; The hypolipemic properties of 2-acetoamidoethyl (p-chlorophenyl)(m-trifluoromethylphenoxy)acetate in the rat (35474). Proceedings of the Society of Experimental Biology and Medicine 136: 1274.
  • 5 Hucker H. B, Grady L. T, Michniewicz B. M, Stauffer S. C, White S. E, Maha G. E, McMahon F. G. 1971; Metabolism of a new hypolipidemic agent, 2-acetomidoethyl(p-chloro-phenyl)(m-trifluoromethylphenoxy)-acetate (halofenate) in the rat, dog, Rhesus monkey and man. Journal of Pharmacology and Experimental Therapeutics 179: 359.
  • 6 Hutchison J. C, Wilkinson W. H. 1973; The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia. Atherosclerosis 18: 353.
  • 7 Sirtori C, Hurwitz A, Sabih K, Azarnoff D. L. 1972; Clinical evaluation of MK-185: a new hypolipidemic drug. Lipids 7: 96.